The company is actively presenting at prestigious investor conferences and highlighting FDA-approved cancer therapies (Revuforj and Niktimvo) with strong clinical data, demonstrating confidence in its pipeline and market position.
Company demonstrates strong commercial momentum with two approved therapies (Revuforj and Niktimvo) generating $172.4 million in 2025 revenue, a 628% increase year-over-year. Stock has surged 83% over the past year, significantly outperforming the S&P 500. Institutional investment from Sphera Funds and accelerating drug adoption indicate confidence in the company's transition from clinical-stage to profitable operations.
Articles that tag SNDX but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
